Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on itching and pain by selectively targeting kappa opioid receptors in the United States. The company is headquartered in Stamford, Connecticut.
Thursday's top analyst upgrades and downgrades included AGNC Investment, Costco Wholesale, CrowdStrike, Dick’s Sporting Goods, Fifth Third Bancorp, General Electric, PayPal, Sabre, Six Flags Entertainment and Solid Power.
Tuesday afternoon's top analyst upgrades and downgrades included Biogen, BP, Caterpillar, Riot Blockchain, Squarespace and more.
Cara Therapeutics shares were crushed on Tuesday after the firm announced results from its midstage trial in patients with chronic kidney disease.
Chris Lange 
